---
title: "Repatha (evolocumab), all indications: Access and coverage questions"
description: "Access and coverage questions on Repatha (evolocumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Cost and coverage, Access and billing, Access and support, Patient support, and Prior authorization. Questions: Does the Repatha SureClick autoinjector cost the same as the prefilled syringe? What are the NDC numbers for Repatha? Is there a Repatha copay card? How much do patients pay for Repatha? 6 further questions follow. 10 questions quoted from 8 sources."
canonical: "https://www.evicenter.com/medical-information/repatha/access-and-coverage"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Repatha (evolocumab), all indications: Access and coverage questions

Manufacturer: Amgen Inc.  
Prescribing information: [Repatha](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf)  
Indication pages: [Cardiovascular event risk reduction](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction)

## Cost and coverage

<a id="repatha-autoinjector-price"></a>

### Does the Repatha SureClick autoinjector cost the same as the prefilled syringe?

> “Q: Is there a difference in the list prices between the prefilled syringe and SureClick<sup>®</sup>
> autoinjector? 
> •
> The list price for the SureClick<sup>®</sup> autoinjector should be the same as the prefilled syringe.”

Source: [REPATHA: Repatha-prefilled-syringe-update-FAQs-for-HCPs, page 1, captured 2026-11-13](https://www.repathahcp.com/~/media/Themes/Amgen/RepathaHcp-com/RepathaHcp-com/Documents/PDFs/Repatha-prefilled-syringe-update-FAQs-for-HCPs#page=1)

Note: This passage is from the prefilled syringe discontinuation FAQ for healthcare providers (dated 2025) that the Repatha HCP site links. It does not state a list price.

<a id="repatha-copay-card"></a>

### Is there a Repatha copay card?

> “Repatha<sup>®</sup> Co-Pay Card
>
> Your commercially insured patients may pay as little as $25 for a 1-month supply or $50 for a 3-month supply with the Repatha<sup>®</sup> Co-Pay Card.”

Source: [REPATHA: AMGEN® SupportPlus, captured 2026-11-13](https://www.repathahcp.com/amgen-supportplus#:~:text=Co%2DPay%20Card,Co%2DPay%20Card.)

> “*Eligibility criteria and program maximums apply. Co-pay support for a 3-month supply
> depends on the patient's insurance, as some plans may impose quantity or dispensing
> limitations. Please see full Terms and Conditions at https://www.repatha.com/copaytcs.”

Source: [REPATHA: AMGEN® SupportPlus, captured 2026-11-13](https://www.repathahcp.com/amgen-supportplus#:~:text=%2AEligibility%20criteria%20and%20program%20maximums,Terms%20and%20Conditions%20at%20https%3A%2F%2Fwww.repatha.com%2Fcopaytcs.)

Note: As captured on November 13, 2026, the Repatha HCP pages state that the card is for commercially insured patients and that eligibility criteria and program maximums apply; they refer to the full Terms and Conditions at repatha.com/copaytcs for the eligibility rules and maximum amounts, which were not captured.

<a id="repatha-cost"></a>

### How much do patients pay for Repatha?

> “OVER 86% OF REPATHA<sup>®</sup> PRESCRIPTIONS cost $50 or less across insurance types<sup>3,‡</sup>”

Source: [REPATHA: Coverage Information, captured 2026-11-13](https://www.repathahcp.com/coverage-information#:~:text=OVER%2086%25%20OF,%2450%20or%20less%20across%20insurance)

> “<sup>‡</sup> Based on IQVIA claims data from 1/1/2025 to 12/31/25 using Commercial and Medicare data. Patient out-of-pocket costs and insurance requirements may vary.”

Source: [REPATHA: Coverage Information, captured 2026-11-13](https://www.repathahcp.com/coverage-information#:~:text=Based%20on%20IQVIA%20claims%20data%20from%201%2F1%2F2025%20to%2012%2F31%2F25,and%20insurance%20requirements%20may%20vary.)

> “Your eligible commercially insured patients may pay as little as $25 for a 1-month supply or $50 for a 3-month supply* with the Repatha<sup>®</sup> (evolocumab) Co-pay Card.”

Source: [REPATHA: HCP Forms & Resources, captured 2026-11-13](https://www.repathahcp.com/forms-and-resources#:~:text=Your%20eligible%20commercially%20insured%20patients,%28evolocumab%29%20Co%2Dpay%20Card.)

> “*Eligibility criteria and program maximums apply. Co-pay support for a 3-month supply depends on the patient's insurance, as some plans may impose quantity or dispensing limitations. Please see full Terms and Conditions at https://www.repatha.com/copaytcs.”

Source: [REPATHA: HCP Forms & Resources, captured 2026-11-13](https://www.repathahcp.com/forms-and-resources#:~:text=%2AEligibility%20criteria%20and%20program%20maximums,Terms%20and%20Conditions%20at%20https%3A%2F%2Fwww.repatha.com%2Fcopaytcs.)

Note: The share of prescriptions costing $50 or less is the manufacturer's figure from IQVIA claims data for calendar year 2025. As captured on November 13, 2026, the Repatha HCP pages state that the card is for commercially insured patients and that eligibility criteria and program maximums apply; they refer to the full Terms and Conditions at repatha.com/copaytcs for the eligibility rules and maximum amounts, which were not captured. The coverage page shows the Medicare and Medicaid out-of-pocket amounts as graphics, so they are not quoted.

<a id="repatha-insurance-coverage"></a>

### What share of patients have insurance coverage for Repatha?

> “~96% OF PATIENTS ARE COVERED FOR REPATHA<sup>®</sup> ACROSS INSURANCE TYPES<sup>1,</sup>*”

Source: [REPATHA: Coverage Information, captured 2026-11-13](https://www.repathahcp.com/coverage-information#:~:text=~96%25%20OF%20PATIENTS%20ARE%20COVERED,ACROSS%20INSURANCE)

> “*Includes commercial, health exchange, Medicaid, and Medicare lives, as of February 2026, based on MMIT data. Inclusion on formulary does not imply superior clinical efficacy or safety. This information is subject to change without notice. For the most up-to-date and complete information regarding coverage of Repatha<sup>®</sup>, please contact the relevant payer directly. Individual insurance requirements may vary.”

Source: [REPATHA: Coverage Information, captured 2026-11-13](https://www.repathahcp.com/coverage-information#:~:text=%2AIncludes%20commercial%2C%20health%20exchange%2C%20Medicaid%2C,Individual%20insurance%20requirements%20may%20vary.)

Note: The coverage figure is the manufacturer's statement based on MMIT data as of February 2026, as captured on November 13, 2026. The claim approval rates on the coverage page are shown as graphics, so they are not quoted.

## Access and billing

<a id="repatha-ndc"></a>

### What are the NDC numbers for Repatha?

> “Not Made with Natural Rubber Latex – 
> Strength 
> Packaging Unit 
> NDC 
> 140 mg/mL prefilled single-dose pen 
> Carton of 2 
> 72511-143-02 
> 140 mg/mL prefilled single-dose pen 
> Carton of 1 
> 72511-143-01 
> 140 mg/mL prefilled single-dose SureClick<sup>®</sup> autoinjector  
> Carton of 2 
> 72511-393-02 
> 140 mg/mL prefilled single-dose SureClick<sup>®</sup> autoinjector  
> Carton of 1 
> 72511-393-01 
> 140 mg/mL prefilled single-dose syringe 
> Carton of 1 
> 72511-501-01 
>
> Contains Dry Natural Rubber – 
> Strength 
> Packaging Unit 
> NDC 
> 140 mg/mL prefilled single-dose SureClick<sup>®</sup> autoinjector* 
> Carton of 2 
> 72511-760-02 
> 140 mg/mL prefilled single-dose syringe* 
> Carton of 1 
> 72511-750-01 
> * The needle cover of the glass prefilled single-dose SureClick<sup>®</sup> autoinjector and prefilled single-dose syringe contain dry 
> natural rubber (a derivative of latex) that may cause allergic reactions in individuals sensitive to latex [see Warnings and 
> Precautions (5.1)].”

Source: [REPATHA: Prescribing information, page 26, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=26)

> “Transition all refill patients to the SureClick<sup>®</sup> autoinjector (NDC 72511-393-02).”

Source: [REPATHA: Prefilledsyringeupdate, captured 2026-11-13](https://www.repathahcp.com/prefilledsyringeupdate#:~:text=Transition%20all%20refill%20patients%20to,autoinjector%20%28NDC%2072511%2D393%2D02%29.)

Note: The NDC table is from the Prescribing Information revised 10/2026, which lists each strength, packaging unit, and NDC in that order. The prefilled syringe (NDC 72511-501-01) is the presentation the Repatha HCP site, as captured on November 13, 2026, describes as discontinued; the site's notice does not address the dry natural rubber cartons (72511-760-02 and 72511-750-01).

## Access and support

<a id="repatha-amgennow"></a>

### Can patients get Repatha directly from Amgen (AmgenNow)?

> “Repatha<sup>®</sup> is now available through AmgenNow<sup>TM</sup>, a direct-to-patient program.”

Source: [REPATHA: Coverage Information, captured 2026-11-13](https://www.repathahcp.com/coverage-information#:~:text=is%20now%20available%20through,a%20direct%2Dto%2Dpatient%20program.)

Note: As captured from the coverage page of the Repatha HCP site on November 13, 2026. The page states no price or eligibility terms for the program.

## Patient support

<a id="repatha-supportplus"></a>

### What support does Amgen SupportPlus offer Repatha patients?

> “We know every patient has unique needs. We’re here to provide financial support information and resources, regardless of their current financial situation or type of insurance they have.”

Source: [REPATHA: AMGEN® SupportPlus, captured 2026-11-13](https://www.repathahcp.com/amgen-supportplus#:~:text=We%20know%20every%20patient%20has,type%20of%20insurance%20they%20have.)

> “Amgen Nurse Partners can provide supplemental support, including:
>
> Supplemental injection education and support
> Guidance on resources that may help lower out-of-pocket medication costs
> Assistance to help your patients stay on track with their medication
> Answers to questions about Amgen SupportPlus”

Source: [REPATHA: AMGEN® SupportPlus, captured 2026-11-13](https://www.repathahcp.com/amgen-supportplus#:~:text=Amgen%20Nurse%20Partners%20can%20provide,to%20questions%20about%20Amgen%20SupportPlus)

> “Your patients can enroll in the Amgen Nurse Partner Program online at repatha.com or by calling 1-844-REPATHA (1-844-737-2842).”

Source: [REPATHA: AMGEN® SupportPlus, captured 2026-11-13](https://www.repathahcp.com/amgen-supportplus#:~:text=Your%20patients%20can%20enroll%20in,or%20by%20calling%201%2D844%2DREPATHA%20%281%2D844%2D737%2D2842%29.)

> “Amgen Nurse Partners are only available to patients that are prescribed certain Amgen products. They are not part of your patient’s treatment team and do not provide medical advice, nursing, or case management services. Amgen Nurse Partners will not inject patients with Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.”

Source: [REPATHA: AMGEN® SupportPlus, captured 2026-11-13](https://www.repathahcp.com/amgen-supportplus#:~:text=Amgen%20Nurse%20Partners%20are%20only,medical%20decisions%20or%20treatment%20concerns.)

<a id="repatha-injection-support"></a>

### Is injection support available for Repatha patients?

> “Supplemental injection support is available for patients who need assistance.<sup>2,‡</sup>”

Source: [REPATHA: Dosing and Administration, captured 2026-11-13](https://www.repathahcp.com/dosing-and-administration#:~:text=Supplemental%20injection%20support%20is%20available%20for%20patients%20who%20need)

> “<sup>‡</sup>Amgen<sup>®</sup> nurse partners can provide patients live (over the phone) supplemental injection support at 1-844-REPATHA.”

Source: [REPATHA: Dosing and Administration, captured 2026-11-13](https://www.repathahcp.com/dosing-and-administration#:~:text=nurse%20partners%20can%20provide%20patients,supplemental%20injection%20support%20at%201%2D844%2DREPATHA.)

## Prior authorization

<a id="repatha-prior-authorization"></a>

### What help is available for Repatha prior authorization?

> “Contact your Field Access Specialist for live or virtual support, that includes:
>
> Help with navigating prior authorization, appeals, and fulfillment processes
> Educating on payer requirements and necessary documentation for individual patient support
> Answers to general questions about Amgen SupportPlus programs and other available resources
> Navigating the benefit verification process”

Source: [REPATHA: AMGEN® SupportPlus, captured 2026-11-13](https://www.repathahcp.com/amgen-supportplus#:~:text=Contact%20your%20Field%20Access%20Specialist,Navigating%20the%20benefit%20verification%20process)

> “Sample Letter of Medical Necessity
>
> This sample letter is a template that can be used to support the clinical rationale for prescribing Repatha<sup>®</sup>, if required to accompany a prior authorization.”

Source: [REPATHA: HCP Forms & Resources, captured 2026-11-13](https://www.repathahcp.com/forms-and-resources#:~:text=Sample%20Letter%20of%20Medical%20Necessity,to%20accompany%20a%20prior%20authorization.)

> “Physician Patient Documentation Checklist
>
> This checklist can organize specific information about patients’ diagnosis and treatment history to help complete a prior authorization.”

Source: [REPATHA: HCP Forms & Resources, captured 2026-11-13](https://www.repathahcp.com/forms-and-resources#:~:text=Physician%20Patient%20Documentation%20Checklist,help%20complete%20a%20prior%20authorization.)

> “Consult payer coverage policy for prior authorization criteria and documentation requirements.”

Source: [REPATHA: Physician-Patient-Documentation_Checklist.pdf, page 1, captured 2026-11-13](https://www.repathahcp.com/-/media/Themes/Amgen/RepathaHcp-com/RepathaHcp-com/Documents/PDFs/Physician-Patient-Documentation_Checklist.pdf#page=1)

Note: The last passage is from the Physician Patient Documentation Checklist that the forms and resources page links.

<a id="repatha-appeal-letter"></a>

### Is there a Repatha appeal letter template?

> “Sample Letter of Appeal
>
> This sample letter is a template that can be used to support the clinical rationale for prescribing Repatha<sup>®</sup>. This can be used during the appeals process.”

Source: [REPATHA: HCP Forms & Resources, captured 2026-11-13](https://www.repathahcp.com/forms-and-resources#:~:text=Sample%20Letter%20of%20Appeal,used%20during%20the%20appeals%20process.)

## Related pages
- [Medical information: Repatha (evolocumab): All indications](https://www.evicenter.com/medical-information/repatha)
- [Indication](https://www.evicenter.com/medical-information/repatha/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/repatha/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/repatha/safety)
- [Specific populations](https://www.evicenter.com/medical-information/repatha/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/repatha/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/repatha/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/repatha/storage-and-supply)
